Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms, Nerve Tissue 2Neoplasms 2Glioma 2Glioblastoma 2Brain Neoplasms 2

Interventions

Temozolomide 41Magnetic Resonance Spectroscopy 21Radiotherapy 19Specimen Handling 15Radiation 12Bevacizumab 11Lomustine 9pembrolizumab 6fludarabine 5Surgical Procedures, Operative 5atezolizumab 4Nivolumab 4Ipilimumab 4Cyclophosphamide 4Carboplatin 4Biopsy 4cemiplimab 3azeliragon 3Immunoglobulin G 3Disulfides 3Aminolevulinic Acid 3veliparib 2trametinib 2rocakinogene sifuplasmid 2ribociclib 2poly ICLC 2pamiparib 2olaparib 2niraparib 2lutetium Lu 177 dotatate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × contrast agent BR1 × 90 days × Clear all
NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NaviFUS Corporation

Phase 1/2 Recruiting
10 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06496971 2026-04-09

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

NaviFUS Corporation

Phase 3 Recruiting
32 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡